Shionogi & Co (4507.T) Stock Price
Shionogi & Co Price
Over the last 19 years Shionogi & Co grew revenue by 4.9% annually, reaching 499.68 B JPY. Earnings per share have grown at 13.5% per year over the last 19 years. For Shionogi & Co, the net margin of 41.1% is up versus 34.1% a few years ago. At today's price the dividend yield works out to roughly 3.73%. The payout ratio is around 29% of earnings. The dividend has grown at 16.2% per year over the past 19 years. The consensus 12-month price target for Shionogi & Co is 3,162.00 JPY, about 13.3% above where the stock trades today. Of 17 analysts, 7 rate the stock a buy — an overall Hold consensus.
Shionogi & Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Shionogi & Co business model & stock analysis
Frequently asked questions about Shionogi & Co
Shionogi & Co Ltd is a pharmaceutical company that focuses on developing and marketing innovative drugs. Their business model revolves around research and development, manufacturing, and sales of pharmaceutical products. Shionogi aims to provide solutions to unmet medical needs by focusing on therapeutic areas such as infectious diseases, pain, cardiovascular disorders, and oncology. By investing in cutting-edge research, Shionogi strives to create new treatments and improve existing therapies. With a strong commitment to quality and patient-centric approach, Shionogi seeks to contribute to the well-being of society by delivering safe, effective, and high-quality pharmaceutical products.
Shionogi & Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Shionogi & Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc., and Daiichi Sankyo Co Ltd.
Shionogi & Co Ltd is a renowned pharmaceutical company based in Japan. With a rich history dating back to 1878, Shionogi has established itself as a leading player in the global healthcare industry. The company is known for its focus on research and development, aiming to discover innovative solutions to various medical challenges. Shionogi's commitment to addressing unmet medical needs has led to the development of groundbreaking drugs and treatments. Over the years, Shionogi has expanded its operations worldwide, forming strategic partnerships and collaborations to deliver high-quality pharmaceutical products to patients around the globe. Through a steadfast dedication to improving human health, Shionogi has become a respected name in the pharmaceutical field.
Shionogi & Co Ltd has achieved several significant milestones throughout its history. In recent years, the company successfully developed and gained approval for several groundbreaking medications, including the antiretroviral drug Delstrigo™ and the antibiotic Fetroja™. Shionogi has also established strategic partnerships with renowned pharmaceutical companies to enhance its research and development capabilities. Additionally, the company has been actively expanding its global reach, particularly in the United States and Europe, through various initiatives and collaborations. With an impressive track record of innovation and a commitment to improving global health, Shionogi & Co Ltd continues to make significant strides in the pharmaceutical industry.
Shionogi & Co Ltd is primarily present in Japan, where the company is headquartered.
Shionogi & Co Ltd represents values of innovation, integrity, and commitment to improving global health. The company's corporate philosophy is centered around the "Supplier of smiles" concept, aiming to contribute to the quality of life and healthcare of people worldwide. Shionogi is dedicated to delivering innovative pharmaceuticals and healthcare solutions, focusing on areas such as infectious diseases, cancer, pain management, and neuroscience. The company's emphasis on research and development, ethical practices, and strong partnerships enables Shionogi to fulfill its mission of creating a healthier future for society.
Analysts currently set an average price target of 3,178.69 JPY for the Shionogi & Co stock (median: 3,162.00 JPY), implying +13.9 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Shionogi & Co stock: 7 recommend buying, 10 holding and 0 selling.
Converted at the current exchange rate, the Shionogi & Co share trades at 15.75 EUR (2,790.00 JPY).
The Shionogi & Co share (4507.T) is listed on 5 stock exchanges, including: Tokio (JPX) (4507.T), Frankfurt (SH0.F), München (SH0.MU), Düsseldorf (SH0.DU).
Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. The company was founded in 1878 and specializes in the development and marketing of innovative drugs. Shionogi combines its own research capabilities with strategic partnerships with other companies. The business model of Shionogi is based on three core divisions: 1. Pharma: This division includes the clinical development and marketing of prescription drugs. Shionogi has a wide range of medications in various therapeutic areas such as oncology, infectious diseases, diabetes, cardiovascular diseases, and neurological diseases. One of Shionogi's most well-known medications is the antibiotic Fetroja for the treatment of respiratory and urinary tract infections. 2. Consumer Healthcare: This division includes the development and marketing of over-the-counter products such as dietary supplements or cosmetics. Some of Shionogi's well-known products include Dequadin lip balm, which helps with chapped lips and cold sores, and Allelock antiallergic medication used for allergic rhinitis. 3. Research & Development: This division focuses on the research and development of innovative drugs and therapy options. Shionogi invests a considerable portion of its revenue in research and development each year. The company also collaborates closely with academic institutions and other pharmaceutical companies to accelerate the research and development of new drugs. Additionally, Shionogi has a strong focus on the Asian market. The company has subsidiaries in several Asian countries and has made significant investments in research facilities in China and Singapore in recent years. In 2020, Shionogi had a revenue of approximately 1.1 trillion yen (around 8.6 billion euros) and employed around 6,000 people in Japan and worldwide. In summary, Shionogi's business model is based on the development and marketing of innovative drugs and therapy options. The company combines its own research capabilities with strategic partnerships and operates in three core divisions: Pharma, Consumer Healthcare, and Research & Development. Shionogi also has a strong presence in the Asian market and has invested in research facilities in China and Singapore in recent years.
The revenue of Shionogi & Co is 499.68 B JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Shionogi & Co is 205.16 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Shionogi & Co is currently 11.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Shionogi & Co stock.
The price-to-sales ratio (P/S) of Shionogi & Co is currently 4.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Shionogi & Co stock.
The Eulerpool Quality Score for Shionogi & Co is 5/10.
The ISIN of Shionogi & Co is JP3347200002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Shionogi & Co is 855648. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Shionogi & Co is 4507.T. The ticker symbol is used to trade Shionogi & Co shares on the stock exchange.
Shionogi & Co stock
Shionogi & Co Peer Group
Shionogi & Co Ticker
Shionogi & Co FIGI
All fundamentals and in-depth analysis of Shionogi & Co
Our stock analysis for Shionogi & Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shionogi & Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.